Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients Journal Article


Authors: Klimek, V. M.; Williams, L.; Chapman, P. B.
Article Title: Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients
Abstract: Melanoma-inhibiting activity (MIA) is a 107 amino-acid protein secreted from melanoma cells and frequently detectable at high concentration in the serum of patients with advanced melanoma. Early studies suggested that MIA may be a useful serum tumor-marker for detection of recurrent or progressive disease. We evaluated the sensitivity of serum MIA levels in predicting the risk of relapse in patients with American Joint Committee on Cancer (AJCC) Stage II, III, and IV melanoma. MIA was measured by ELISA in serum from 39 patients with AJCC Stage II, III, and IV disease at a single time-point 1 month to 5 years after they were rendered free of disease. Twenty-three of the 39 patients recurred, with a median follow-up of 4.5 months. Only four of the 23 patients who recurred had shown elevated MIA values (17% sensitivity). Of the 16 patients who remain free of disease (median follow-up 3.5 years, range 11 months to 6.3 years), one patient had an elevated MIA. There was no significant difference in the proportion of patients with elevated serum MIA between the patients who recurred and those who remained free of disease. In this series, serum MIA was not a sensitive marker for relapse in patients who were clinically free of disease after treatment.
Keywords: adult; clinical article; controlled study; aged; middle aged; unclassified drug; cancer recurrence; advanced cancer; cancer staging; sensitivity and specificity; protein blood level; melanoma; neoplasm proteins; recurrence; tumor marker; enzyme linked immunosorbent assay; time factors; risk assessment; disease progression; protein secretion; elisa; protein derivative; extracellular matrix proteins; relapse-free survival; humans; prognosis; human; male; female; priority journal; article; mia; melanoma inhibiting activity protein
Journal Title: Cytokines Cellular and Molecular Therapy
Volume: 7
Issue: 2
ISSN: 1368-4736
Publisher: Taylor & Francis Group  
Date Published: 2002-01-01
Start Page: 71
End Page: 74
Language: English
DOI: 10.1080/13684730412331302072
PUBMED: 12607797
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Virginia Klimek
    147 Klimek
  2. Paul Chapman
    326 Chapman